How long should injection leuprolide be given in known case of localised ca prostate
Reading File
Searching PubMed
leuprolide androgen deprivation therapy localized prostate cancer duration
Finding Sources
Searching PubMed
androgen deprivation therapy duration localized prostate cancer radiation
Finding Sources
Reading Article
Reading Article
Finding Sources
Reading File
Reading File
Here is a detailed, evidence-based breakdown of leuprolide (LHRH agonist) duration in localized prostate cancer, primarily when used alongside radiation therapy (the main setting where ADT is indicated in localized disease):
Duration of Leuprolide (ADT) in Localized Prostate Cancer
Leuprolide monotherapy is not used as definitive treatment in localized prostate cancer. Its role is as ADT combined with external beam radiotherapy (EBRT), with duration determined by risk stratification.
By Risk Group (NCCN-based)
| Risk Group | ADT Indicated? | Duration |
|---|---|---|
| Low risk | Not indicated | - |
| Favorable intermediate risk | Yes, with EBRT | 4 months (neoadjuvant + concurrent) |
| Unfavorable intermediate risk | Yes, with EBRT | 4-6 months (neoadjuvant 2 months + concurrent ± adjuvant) |
| High risk / Very high risk | Yes, with EBRT | 18-36 months (neoadjuvant 2 months + concurrent + adjuvant) |
What the Evidence Says
Harrison's Principles of Internal Medicine (2025) states directly:
"In patients with unfavorable intermediate-risk prostate cancer, short-course ADT (6 months), when combined with external beam radiotherapy, has demonstrated significant improvements in overall survival... In patients with high-risk localized disease, longer courses of ADT (18-36 months) have proven superior to shorter courses and represent the current standard of care when combined with radiotherapy."
Smith and Tanagho's General Urology (19th ed) table confirms:
- Favorable intermediate risk: 4 months (neoadjuvant + concurrent with EBRT)
- High risk: Neoadjuvant 2 months + concurrent + adjuvant totaling 24-36 months
Latest Meta-Analysis Data (2026)
A landmark individual patient data meta-analysis published in JAMA Oncology (2026) - Zaorsky et al., PMID 41264309 - involving 10,266 patients from 13 phase III trials found:
- 1 intermediate-risk factor: Optimal ADT duration = 0 months (no benefit)
- 2+ intermediate-risk factors: Optimal = ~6 months
- High-risk disease: Optimal = ~12 months (relative benefits plateau; beyond 12 months adds other-cause mortality risk)
- Very high-risk: Benefit from longer ADT is undefined/ongoing
Notably, long-term ADT (>28 months vs 0) was associated with increased other-cause mortality (HR 1.28), meaning duration should be tailored carefully.
The Lancet Oncology (2022) meta-analysis - Kishan et al., PMID 35051385 - showed that adjuvant ADT prolongation (extending from 4-6 months to 18-36 months) improved metastasis-free survival regardless of risk group, age, or radiation dose.
Practical Summary
| Clinical Scenario | Leuprolide Duration |
|---|---|
| Low-risk localized | Not recommended |
| Favorable intermediate-risk + RT | 4 months |
| Unfavorable intermediate-risk + RT | 4-6 months |
| High-risk localized + RT | 18-24 months (traditional standard); newer data suggests 12 months may be sufficient |
| Very high-risk / node-positive | 24-36 months (may add abiraterone to 2 years ADT + RT per STAMPEDE data) |
Note: These durations apply when leuprolide is used as part of combined RT + ADT protocols. When used as primary/palliative ADT alone (e.g., patients unfit for definitive treatment), it is typically continued indefinitely until disease progression or intolerance.
Sources: Harrison's Principles of Internal Medicine 22E, p. 743 | Smith and Tanagho's General Urology 19th Ed | Zaorsky et al., JAMA Oncol 2026 (PMID 41264309) | Kishan et al., Lancet Oncol 2022 (PMID 35051385)
This is a shared conversation. Sign in to Orris to start your own chat.